Congressionally Directed Medical Research Programs (CDMRP) Ovarian Cancer Research Program Funding Opportunities for Fiscal Year 2023 (FY23)
The FY23 Defense Appropriations Act provides funding for the Ovarian Cancer Research Program (OCRP) to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service Members, Veterans, their family members, and all women impacted by this disease. The managing agent for the funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The FY23 OCRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. .
Applications submitted to the FY23 OCRP must address one or more of the following Areas of Emphasis:
- Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics, proteogenomics and other critical events
- Develop novel therapeutic strategies for treatment and prevention
- Identify and develop new strategies for screening, early-stage detection, prevention, accurate diagnosis, and prognosis
- Identify and implement strategies to improve the survivorship and quality of life
- Address health disparities
- Improve precision medicine
Alternatively, with adequate justification, applications may identify and address another area of importance related to the ovarian cancer. Justification must be provided in the application.
https://cdmrp.health.mil/funding/ocrp
Investigator-Initiated Research Award – Preproposal due April 17, 2023
Investigators at or above the level of Assistant Professor (or equivalent).
Partnering PI Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.
• Clinical trials are not allowed.
• If cell lines or animals are used, justification for use is required.
• Research aimed at extending the lives of advanced state and recurrent patients is encouraged.
• Preliminary data are required.
• Pre-application is required; application submission is by invitation only.
- · The maximum allowable funding for the entire period of performance is:
- · $600,000 for direct costs for a single PI.
- · $800,000 for direct costs for Partnering PIs
- · Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
- · The maximum period of performance is 4 years.
Ovarian Cancer Academy Award- Early-Career Investigator – Preproposal due April 17, 2023
Investigators must be within 5 years of their last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent as of the full application submission deadline. A letter attesting to eligibility is required.
Supports the addition of new Early-Career Investigators (ECIs) to the unique, interactive virtual academy that provides intensive mentoring, national networking, collaborations, and a peer group for junior faculty.
• ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
• A Designated Mentor may only mentor one ECI.
• The Designated Mentor is not required to be at the same institution as the ECI.
• Preliminary data are required.
• Clinical trials are allowed.
• Pre-application is required; application submission is by invitation only.
• The maximum allowable funding for the entire period of performance is $725,000 for direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• The maximum period of performance is 4 years
Pilot Award – Preproposal due April 17, 2023
Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent).
Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.
• Innovation is an important review criterion.
• The goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.
• Clinical trials are not allowed.
• Research aimed at extending the lives of advanced-state and recurrent patients is encouraged.
• Pre-application is required and blinded; application submission is by invitation only.
• The maximum allowable funding for the entire period of performance is $300,000 for direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• The maximum period of performance is 2 years.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).
Point of Contact:
CDMRP Help Desk
301-682-5507
help@eBRAP.org
For more information, please contact Jill Sherman at intl.research@lakeheadu.ca .